No Data
Baili Tianheng (688506.SH): The drug clinical trial approval notice for the injectable BL-M08D1 (ADC) project has been obtained for the treatment of relapsed or refractory hematologic malignancies and locally advanced or metastatic solid tumors.
On November 28, Gugonghui reported that Baili Tianheng (688506.SH) announced that the company has recently received the "Clinical Trial Approval Notification" formally issued by the National Medical Products Administration (NMPA), approving the clinical trial of the self-developed innovative cmf cni biomedicineb BL-M08D1 (ADC). BL-M08D1 is an ADC drug derived from the same small molecule technology platform as BL-B01D1 and shares the same "linker + toxin" platform with BL-B01D1, indicated for relapsed or refractory hematologic malignancies and locally advanced or metastatic solid tumors.
Guosheng Securities: The trend of the domestic innovative drug industry is gradually shifting from license-in to license-out.
Against the backdrop of fierce competition and internal circulation of innovative drug targets in the domestic market, going global is expected to break through the profit ceiling of the domestic market and follow the trend of global innovation.
We Think Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Profit Is Only A Baseline For What They Can Achieve
Subdued Growth No Barrier To Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) Price
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Report for the third quarter of 2024
No Data
No Data
